Is neurocrine nears $2.5 billion deal for Soleno Therapeutics?
Neurocrine Biosciences completed a definitive acquisition agreement to purchase Soleno Therapeutics for a total equity valuation of approximately 2.9 billion dollars in cash. The strategic transaction brought Vykat XR—an innovative, FDA-approved treatment for hyperphagia associated with Prader-Willi syndrome—directly into Neurocrine's growing rare disease commercial portfolio. This major corporate buyout expands the company's leadership footprint in specialized endocrinology and reinforces its long-term revenue diversification strategy.
Related FAQs
SmartBank operates as a growing commercial community bank serving regions across the Southeastern United States, establishing a distinct operating model when evaluated against national banking mega-corporations.
Investing in NIO involves assessing its position as an early pioneer and technology leader in premium smart electric vehicles and automated battery exchange services.